共 34 条
[3]
Selective inhibition of cell growth by activin in SNU-16 cells[J]. Young Il Kim,Hee Joo Lee,Inkoo Khang,Byung-Nam Cho,Ha Kyu Lee.World Journal of Gastroenterology. 2006(19)
[5]
Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer[J] . Shaheenah Dawood,Bhawna Sirohi.Future Oncol. . 2015 (6)
[6]
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J] . Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Ruihua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao.Gastric Cancer . 2015 (1)
[7]
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J] . Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,Gy?rgy Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D Sch
[8]
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J] . Timothy Iveson,Ross C Donehower,Irina Davidenko,Sergey Tjulandin,Andrzej Deptala,Mark Harrison,Somanath Nirni,Kuntegowdanahalli Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S Oliner,Elwyn Loh.Lancet Oncol
[9]
FGF Receptors: Cancer Biology and Therapeutics[J] . Masaru Katoh,Hitoshi Nakagama.Med. Res. Rev. . 2014 (2)
[10]
MicroRNAs in Gastric Cancer: From Benchtop to Bedside[J] . Fuyi Tong,Peng Cao,Yuan Yin,Suhua Xia,Rensheng Lai,Shenlin Liu.Digestive Diseases and Sciences . 2014 (1)